Literature DB >> 8938949

Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer.

M Higashiyama1, O Doi, K Kodama, H Yokouchi, R Tateishi.   

Abstract

Immunohistochemical analysis of Bcl-2 oncoprotein, one of the oncogenes associated with the regulation of programmed cell death, was performed on 12 surgically resected tumors of the combined type of small-cell lung cancer. Ten cases (83%) expressed Bcl-2 oncoprotein within the tumor tissues. Two of them showed its expression in both the small cell carcinoma and non-small cell carcinoma types, and 7 cases exhibited Bcl-2 expression only in the portion of the small cell carcinoma. Considering previous reports indicating a high prevalence of Bcl-2 oncoprotein expression in small cell lung cancer, it is suggested that Bcl-2 oncoprotein even in the combined type of lung cancer may play an important role in tumorigenesis and tumor development and ensuing histological alterations between small cell carcinoma and non-small cell carcinoma types.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8938949     DOI: 10.1159/000217998

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  3 in total

1.  Association of the functional BCL-2 rs2279115 genetic variant and small cell lung cancer.

Authors:  Xinyu Yang; Feng Gao; Fei Ma; Yanli Ren; Hongwei Chen; Xue Liang; Sichong Han; Xiangyu Xiong; Wenting Pan; Changchun Zhou; Liqing Zhou; Ming Yang
Journal:  Tumour Biol       Date:  2015-08-27

2.  A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Authors:  Paul K Paik; Charles M Rudin; Andrew Brown; Naiyer A Rizvi; Naoko Takebe; William Travis; Leonard James; Michelle S Ginsberg; Rosalyn Juergens; Susan Markus; Leslie Tyson; Sara Subzwari; Mark G Kris; Lee M Krug
Journal:  Cancer Chemother Pharmacol       Date:  2010-02-18       Impact factor: 3.333

3.  Growth inhibition of DU-145 prostate cancer cells by a Bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide.

Authors:  M J Campbell; M Dawson; H P Koeffler
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.